Shanghai INT Medical Instruments (HKG:1501) is proposing to acquire a controlling stake of at least 51% in Hangzhou Weiqiang Medical Technology, a Wednesday bourse filing said.
The purchase will be executed through a capital injection of at least 200 million yuan and the acquisition of equity interest from certain shareholders of the target firm.
Following a formal agreement regarding the purchase, the capital injected into the firm will be used for working capital and repayment of bank loans and other debts.
Hangzhou Weiqiang Medical Technology mainly engages in research, development, manufacturing, and sale of aortic and peripheral vascular interventional medical devices.
Price (HKD): $27.30, Change: $+0.35, Percent Change: +1.30%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。